Search results
Results from the WOW.Com Content Network
SSRIs are modern antidepressants often used as a first-line treatment for major depressive disorder. Common SSRIs include Prozac (fluoxetine), Zoloft (sertraline) and Lexapro (escitalopram ...
Lexapro, Paxil and Cymbalta carry a higher risk of packing on pounds than Zoloft, while Wellbutrin users are less likely to gain weight, according to a new study of eight popular antidepressants ...
After six months, those who took Lexapro, Paxil, or Cymbalta had a 10% to 15% higher risk of gaining weight (which was defined as at least 5% of their baseline weight), compared with those who ...
However, the SNRIs are among the most widely used antidepressants today. In 2009, Cymbalta and Effexor were the 11th- and 12th-most-prescribed branded drugs in the United States, respectively. This translates to the 2nd- and 3rd-most-common antidepressants, behind Lexapro (escitalopram), an SSRI. [87]
Lexapro (escitalopram) – an antidepressant of the SSRI class; Librium (chlordiazepoxide) – a benzodiazepine used to treat acute alcohol withdrawal; Lithobid, Eskalith – a mood stabilizer; Loxam (escitalopram) – an antidepressant of the SSRI class; Lunesta (eszopiclone) – a non-benzodiazepine hypnotic
While clinical trials of psychiatric medications, like other medications, typically test medicines separately, there is a practice in psychiatry (more so than in somatic medicine) to use polypharmacy in combinations of medicines that have never been tested together in clinical trials (though all medicines involved have passed clinical trials ...
Both brand name Lexapro and generic escitalopram are considered SSRIs, or selective serotonin reuptake inhibitors, a class of medications commonly used to treat major depressive disorder, anxiety ...
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.